Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma

@article{Plotkin2009SuggestedRC,
  title={Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma},
  author={Scott Randall Plotkin and Chris Halpin and Jaishri O Blakeley and William H. Slattery and D Bradley Welling and Susan M. Chang and Jay Steven Loeffler and Gordon J. Harris and A. Gregory Sorensen and Michael J. McKenna and Fred G. Barker},
  journal={Journal of Neuro-Oncology},
  year={2009},
  volume={93},
  pages={61-77}
}
Neurofibromatosis type 2 (NF2) is a tumor suppressor gene syndrome characterized by multiple schwannomas, especially vestibular schwannomas (VS), and meningiomas. Anticancer drug trials are now being explored, but there are no standardized endpoints in NF2. We review the challenges of NF2 clinical trials and suggest possible response criteria for use in initial phase II studies. We suggest two main response criteria in such trials. Objective radiographic response is defined as a durable 20% or… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 153 references

Activity of bevacizumab against NF2-related vestibular schwannomas

  • SR Plotkin, C Halpin, +4 authors E. Di Tomaso
  • Neuro-Oncology
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…